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Introduction
Microcystic stromal tumor (MCST) of the ovary is a rare sub-
type of ovarian tumor with less than 30 cases reported world-
wide [1-6]. It is a new disease entity first described by Irving 
and Young in 2009 [1] based on 16 cases of uncategorized 
ovarian tumors. The distinctive histological characteristics of 
the tumor include: a microcystic pattern and regions with lob-
ulated cellular masses with intervening, sometimes hyalinized, 
fibrous stroma; an absence of morphologic features enabling 
any other specific diagnosis in the sex cord-stromal category; 
an absence of epithelial elements; and an absence of tera-
tomatous or other germ cell elements. Immunohistochemi-
cally, MCST cells are strongly positive for CD10, vimentin, and 
Wilms tumor 1, and negative for sex-cord stromal markers 
(α-inhibin and calretinin) and epithelial membrane antigen. 
The origin and genetic background of ovarian MCST is still 
unclear. In 2011, Maeda et al. [2] reported β-catenin gene 
(CTNNB1) mutation and high nuclear expression of β-catenin 
in two cases of ovarian MCST. Several more reports that muta-
tion in β-catenin gene (CTNNB1) is related with ovarian MCST 
followed [3-6]. In this study, we report two cases of ovarian 
MCST, along with the β-catenin gene (CTNNB1) mutation in 
exon 3 that was also detected in both cases. This is the first 
report of the detection of CTNNB1 mutation in ovarian MCST 
using pyrosequencing.  
Case report
1. Case 1 
A 24-year-old female, gravida 0, visited the outpatient depart-
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ment because of lower abdominal discomfort for a week. 
After physical evaluation, the patient underwent computed 
tomography (CT), which showed an 18×12-cm multilocular 
cystic mass originating from the left adnexa. The cyst present-
ed features of benign epithelial ovarian cyst such as smooth 
outer wall and thin internal sepation (Fig. 1A). Serum levels of 
CA-125 and CA-19-9 were within normal limits. The patient 
underwent laparoscopic salpingo-oopherecomy. Due to mate-
rial insufficiency, the result of intraoperative frozen biopsy was 
non-diagnostic. Finally, the patient was diagnosed as MCST. 
No adjuvant treatment was performed. The patient is currently 
free of disease after 8 months from surgery.
2. Case 2
A 31-year-old woman, gravida 0, who presented with a 
palpable mass at lower abdomen was referred to a tertiary 
healthcare institution. Pelvis CT and pelvis magnetic resonance 
imaging revealed a 24-cm-sized left ovarian mass with solid 
and cystic portion. The mass presented thick outer wall with 
irregular margin (Fig. 1B, C). For further examination, posi-
tron emission tomography (PET)-CT was performed. On PET-
CT, intense 18-fluoro-2-doxy-D-glucose uptake was shown at 
24-cm-sized left ovarian mass and several lymph nodes in aor-
tocaval space and left paraaortic space, which suggested ovar-
ian malignancy with lymph node metastasis (Fig. 1D-F). Eleva-
tion of tumor markers reflected ovarian epithelial tumor. CA-
125 was elevated at 205.3 IU/L (normal range, 0 to 35 IU/L). 
Human epididymis protein 4 was slightly elevated at 69.1 IU/
L (normal range, 0 to 67 IU/L). The patient underwent staging 
laparotomy including left salpingo-oopherecomy, paraaortic 
lymph node sampling, and abdominal peritonectomy. The re-
sult of intraoperative frozen pathology was “favoring sex cord 
stromal tumor”. After the immunohistochemical examination, 
the patient was finally diagnosed as MCST and paraaortic 
lymph nodes were free from tumor. Without adjuvant therapy, 
she is currently free of disease after 3 months after surgery 
and scheduled for follow-up after 6 months. 
3. Pathologic findings
Grossly, the resected specimen of case 1 was fragmented 
tumor tissues (18×12 cm), consisting of a relatively well-cir-
cumscribed cystic mass, necrotic material, and blood clots (Fig. 
2A). The cystic wall containing tumor tissue showed a smooth 
outer surface and internal thin, fibrous septae. No definite 
solid lesion was identified. The specimen of case 2 was a well-
circumscribed, multilobulated cystic mass measuring 20×14 
cm and weighing 80 g (Fig. 2B). Extensive tumor necrosis was 
identified within the mass. Multifocal solid lesions were identi-
fied. There was no capsular involvement. 
Microscopically, the tumor consisted of three histologic 
components: solid sheets of tumor cells, numerous microcysts, 
and intervening bundles of hyalinized fibrous bands within the 
stroma (Fig. 2C, D). The variable-sized microcysts were lined 
with bland-appearing tumor cells (Fig. 2E, F). The individual 
tumor cells had uniform, small, round nuclei with inconspicu-
ous nucleoli and abundant granular, eosinophilic cytoplasm. 
Immunohistochemically, the tumor cells exhibited cytoplasmic 
immunoreactivity for CD10, CD99, and vimentin (Fig. 3A), 
as well as diffuse and strong nuclear immunoreactivity for 
β-catenin (Fig. 3B).
In addition, pyrosequencing revealed a point mutation (S33C) 
in exon 3 of CTNNB1 (Fig. 3C, D), confirming the diagnosis of 
ovarian MCST. 
Discussion 
MCST of the ovary is a newly categorized ovarian tumor first 
described by Irving and Young in 2009 [1] based on 16 cases 
of uncategorized ovarian tumors. Although MCST is some-
times mistaken for the coma due to its thick hyalinized fibrous 
band, it has distinctive microscopic features of solid, micro-
cystic or macrocystic patterns, and uniform and round tumor 
cells with low number of mitotic figures [4,7]. Behavior of the 
tumor is not well known because of limited follow-ups. The 
available information would suggest it is likely benign in most 
cases [1]. 
As the name hints, the origin of ovarian MCST is thought to 
be stroma. Irving and Young suggested possibility of stromal 
origin by excluding other origins. MCST’s characteristic im-
munoprofile (CD10-positive, vimentin-positive, and epithelial 
membrane antigen-negative) and ultrastructural analysis also 
supports the possibility of stromal origin. However, Maeda et 
al. [2] insisted MCST should be classified as “tumors of uncer-
tain origin” considering the pluripotency of the tumor cells. 
In 2011, Maeda et al. [2] reported β-catenin gene (CTNNB1) 
mutation and high nuclear expression of β-catenin in two 
cases of ovarian MCST. Since 2011, eleven more MCST cases 
were reported, with β-catenin gene (CTNNB1) mutation con-
firmed in eight cases [3-6]. β-catenin is a regulatory protein in 
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Fig. 1. (A) Computed tomography (CT) findings of case 1. An 18×12-cm-sized cystic mass with smooth outer wall with no definite solid 
portion, suggesting benign epithelial ovarian tumor. (B) CT findings of case 2 presents a 24-cm-sized solid and cystic left ovarian mass, 
suspicious for malignant epithelial tumor. No pathologically enlarged lymph node or seeding mass was observed in the imaging study. (C) 
Magnetic resonance imaging findings of case 2 suggests malignant epithelial tumor of ovary. (D-F) Positron emission tomography-CT find-
ings of case 2 shows intense uptake by a 24-cm-sized left ovarian mass and several lymph nodes in aortocaval space and left paraaortic 
space, which suggests ovarian malignancy with lymph node metastasis.
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Fig. 2. Gross (A,B) and microscopic (C-F) findings. (A) Case 1. Fragmented specimen shows an admixture of gray-to-yellow, viable tumor tis-
sues and red-to-tan, necrotic and hemorrhagic tissues. (B) Case 2. The resected specimen reveals a cystic mass displaying extensive internal 
tumor necrosis and hemorrhage. The cystic wall has multiple areas of irregular, nodular thickening, indicating viable tumor tissues. (C)  Low-
power view of case 1. Small, irregular, occasionally coalescing cystic spaces are lined by bland cells (H&E, ×100). (D) Low-power view of case 
2. An area showing solid component exhibits similar nuclear features (H&E, ×40). (E,F) High-power views of (E) case 1 (H&E, ×400) and (F) 
case 2 demonstrate uniform, small, round to ovoid nuclei with absent or inconspicuous nucleoli. No mitotic activity is detected (H&E, ×200).
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Fig. 3. Immunohistochemical findings (A,B) and pyrosequencing results (C,D). Immunostaining reveals the tumor cells are positive for (A) 
vimentin (immunohistochemistry; HRP-multimer method, ×200). (B) In addition, diffuse and strong nuclear immunoreactivity for β-catenin 
was identified, suggesting the nuclear translocation and accumulation of β-catenin protein in the individual tumor cells (immunohisto-
chemistry; HRP-multimer method, ×400). (C,D) Pyrograms of a DNA sequence featuring a point mutation involving a single base pair sub-
stitution (c.98C>G; pS33C) in exon 3 of CTNNB1 gene. The mutated site is highlighted in blue and the allele frequencies are given in each 
table. (C) Case 1. (D) Case 2.
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cell to cell adhesion and gene transcription [8]. Dysregulation 
of β-catenin signaling is known to be associated with malig-
nancies, such as colon cancer, hepatocellular carcinoma, and 
endometrial cancer [3,9]. Nature of the β-catenin protein and 
frequent expression rate of β-catenin gene (CTNNB1) muta-
tion in MCST suggests β-catenin plays an important role in 
pathogenesis of the tumor. 
However, there are few cases of non-β-catenin gene (CTN-
NB1) mutation MCST. Recently, Lee et al. reported a case of 
ovarian MCST in a familial adenomatous polyposis patient. 
In this case, the β-catenin gene (CTNNB1) mutation was not 
detected. Instead, a somatic mutation of the APC gene in 
exon 11, with a heterozygous deletion at nucleotide position 
c.1540delG was discovered. Yang and Bhattacharjee [3] re-
ported a case of ovarian MCST with aberrant accumulation of 
nuclear p27 protein. Because p27Kip1 is regarded as tumor sup-
pressor gene [10], Yang and Bhattacharjee [3] described the 
possibility that dysregulation of p27Kip1 plays a role in develop-
ment of MSCT. However, there have been no further studies 
about the relationship between accumulation of p27 protein 
and MCST. Also in this study, genetic analysis was performed 
for only CTNNB1 mutation which is known as the key gene 
alteration of MSCT. 
One more thing to emphasize is that pyrosequencing was 
conducted for gene analysis. Pyrosequencing is a novel meth-
od of DNA sequencing based on the sequencing by synthesis. 
It takes less time and little effort analyzing genetic alteration, 
compared to conventional Sanger sequencing. This result will 
help deciding methods for genetic analysis in future MCST 
studies. 
In conclusion, we report two cases of ovarian MCST with 
its unique histologic and immunohistochemical characters. 
Through the use of pyrosequencing, a point mutation in 
β-catenin gene in exon3 was confirmed. As far as we know, 
β-catenin gene mutation is the key gene alteration of MSCT. 
Ovarian MCST is known as benign ovarian tumor, and further 
studies of its genetic background, treatment, and prognosis 
are needed.  
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